Eyconis announced it raised $60.3 Million in an initial filing from an offering of $150 Million

Company

Location

About

Eyconis, Inc. is a privately held, pre-clinical stage biopharmaceutical company focused on transforming the ophthalmology treatment paradigm through the development, manufacture, and commercialization of novel, best-in-class therapeutics for eye diseases. The Company is advancing a pipeline of therapeutic candidates addressing areas of high unmet need including wet age-related macular degeneration (AMD). Eyconis is partnered with a syndicate of leading biopharma investors including Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital.